Sorry! It's tempting to try this-- why wouldn't we want to empirically give something that could reduce bleeding? If we got a TEG or ROTEM and it was strongly suggestive of hyperfibrinolysis, then sure, we could do that. We shouldn't be doing this empirically, however. The largest RCT on this subject looked at short-term therapy with TXA versus placebo up to the point of aneurysm securing, up to 24 hours. There was no statistically significant difference in rebleeding events and no improvement in functional outcomes at 6 months. A subsequent meta-analysis found no improvement in mortality or functional outcome. Thus, the 2023 AHA/ASA guidelines recommend against the routine usage of TXA for aSAH.
Copyright © 2024-2025 Andrew M. Nguyen, M.D. For educational use only.
This work is licensed under
CC BY-NC-SA 4.0.
